Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | VCP | P55072 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5960509 | 0.90 | KDM4E (0.51) | HRH3ALDH1A1KDM4EHPGDRAB9A | |
| SCHEMBL6253984 | 0.87 | HRH3 (0.56) | HRH3ALDH1A1VCPKDM4EKMT2A | |
| SCHEMBL10066931 | 0.85 | MMP2 (0.59) | HRH3VCPSIRT1F2MMP2 | |
| SCHEMBL20570792 | 0.85 | HRH3 (0.52) | HRH3ALDH1A1KDM4EHPGDTHRB | |
| SCHEMBL30457877 | 0.85 | HRH3 (0.52) | HRH3ALDH1A1KDM4EHPGDTHRB | |
| SCHEMBL6152137 | 0.84 | HRH3 (0.53) | HRH3ALDH1A1KDM4EHPGDTHRB | |
| SCHEMBL6240732 | 0.83 | KDM4E (0.51) | HRH3ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL2974997 | 0.83 | HRH3 (0.51) | HRH3ALDH1A1KDM4EHPGDTHRB | |
| SCHEMBL5882117 | 0.83 | MEN1 (0.49) | HRH3ALDH1A1VCPKDM4EKMT2A | |
| SCHEMBL26926590 | 0.83 | HRH3 (0.55) | HRH3ALDH1A1KDM4EHPGDTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998007716-A2 | HETEROAROTINOIDS-ANTICANCER AGENTS WITH RECEPTOR SPECIFICITY AND TGASE ACTIVITY | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 1998-02-26 | — | — | WO | claimed |
| EP-3675847-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| EP-0959881-B1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN INC (US) | 2005-09-21 | — | — | EP | disclosed |
| US-6750240-B2 | FORMING 2,5-DIHYDROXY-3,6-DI(2-(3-METHYL-N-BUTYL)INDOL-3-YL)-1,4-QUINONE BY REACTING 2,3,5,6-TETRABROMO-1,4-BENZOQUINONE WITH 2-(3-METHYL-N-BUTYL)INDOLE IN PRESENCE OF CESIUM CARBONATE; ANTICANCER AGENTS | SUGEN, INC. | 2004-06-15 | — | — | US | disclosed |
| US-6660763-B2 | Antiproliferative agents for disorders with GRB-2 adaptor protein function; treating diabetes, insulin resistance, insulin deficiency and insulin allergy | SUGEN, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030060635-A1 | Methods of using bis-indolylquinones | TANG PENG C (US) | 2003-03-27 | — | — | US | disclosed |
| US-20020156116-A1 | Bis-indolyquinone compounds | TANG PENG CHO (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1218342-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | Sugen, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6376529-B1 | INSULIN DISEASES; ANTIDIABETIC AGENTS | SUGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| US-20020016353-A1 | Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions | SUGEN INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001021589-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | SUGEN, INC. (US) | 2001-03-29 | — | — | WO | disclosed |
| US-6110957-A | ANTITUMOR AGENT TREATING CELL PROLIFERATIVE DISORDERS SUCH AS CANCER, DYES, FUNGICIDES, BACTERICIDES | SUGEN, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6090838-A | USING 2,5-BISINDOL-3-YL-1,4-QUINONE | SUGEN, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0959881-A1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | Sugen, Inc. (US) | 1999-12-01 | — | — | EP | disclosed |
| CN-1192680-A | Methods and compositions for inhibiting adaptor protein/tyrosine kinase interactions | SUGEN INC (US) | 1998-09-09 | — | — | CN | disclosed |
| US-5786488-A | DEHYDROBROMINATION OF A DIBROMOBENZOQUINONES WITH AT LEAST ONE INDOLES IN A POLAR SOLVENT AND A METAL CARBONATE TO FORM AN ANTITUMOR AGENT | SUGEN, INC. (US) | 1998-07-28 | — | — | US | disclosed |
| US-5780496-A | Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions | SUGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998020874-A1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| EP-0831809-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF ADAPTOR PROTEIN/TYROSINE KINASE INTERACTIONS | Sugen, Inc. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040115-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF ADAPTOR PROTEIN/TYROSINE KINASE INTERACTIONS | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156116-A1 | Bis-indolyquinone compounds | IRS1, GRK2, GID4 | HRH3 1417/4885ALDH1A1 4519/4885VCP 3881/4885 |
| US-20030060635-A1 | Methods of using bis-indolylquinones | IDO2, IDO1, IPO5 | HRH3 963/4885ALDH1A1 2437/4885VCP 2990/4885 |
| US-20020016353-A1 | Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions | GRB2, NCK1, ABL1 | HRH3 2440/4885ALDH1A1 4447/4885VCP 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.